{"disease":{"id":"blastoid-mantle-cell-lymphoma","name":"Blastoid Mantle Cell Lymphoma","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"tumor-tissue","indication_name":"Blastoid Mantle Cell Lymphoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tumor Tissue","generic_name":"tumor-tissue","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02427620","title":"Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":131,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05861050","title":"Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT03946878","title":"Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":32,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}